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There are several lines of evidence indicating that the physiopathological bases of bullous
pemphigoid (BP), the most common subepidermal autoimmune bullous disease, are
hallmarked by the production of autoantibodies directed against the hemidesmosomal
anchoring proteins BP180 and BP230. In contrast to the robustness of the latter
assumption, the multifaceted complexity of upstream and downstream mechanisms
implied in the pathogenesis of BP remains an area of intense speculation. So far, an
imbalance between T regulatory cells and autoreactive T helper (Th) cells has been
regarded as the main pathogenic factor triggering the autoimmune response in BP
patients. However, the contributory role of signaling pathways fostering the B cell
stimulation, such as Toll-like receptor activation, as well as that of ancillary inflammatory
mechanisms responsible for blister formation, such as Th17 axis stimulation and the
activation of the coagulation cascade, are still a matter of debate. In the same way,
the pathomechanisms implied in the loss of dermal-epidermal adhesion secondary to
autoantibodies binding are not fully understood. Herein, we review in detail the current
concepts and controversies on the complex pathogenesis of BP, shedding light on the
most recent theories emerging from the literature.
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INTRODUCTION
Bullous pemphigoid (BP), the most common autoimmune bullous disease, typically presents with
generalized crops of tense, pruritic cutaneous blisters and mostly affects the elderly (1). In up to
20% of cases, BP may initially exhibit a non-bullous phase characterized by eczematous, excoriated,
urticaria-like or nodular lesions, which may last weeks, months, or occasionally remain the sole
clinical manifestation (2). Together with mucous membrane pemphigoid, pemphigoid gestationis,
linear immunoglobulin (Ig) A bullous dermatosis (LABD), anti-laminin γ1 pemphigoid, and
epidermolysis bullosa acquisita (EBA), BP is encompassed in the heterogeneous group of
subepithelial autoimmune bullous disorders (1). Indeed, the histopathological assessment of a
recent blister generally reveals a dermal-epidermal split associated with a dermal inflammatory
infiltrate mainly consisting of lymphocytes and eosinophils (3). In BP, blisters are caused by
autoantibodies of the IgG class directed against two structural components of the hemidesmosome,
a multiprotein complex of the dermal-epidermal junction providing structural adhesion between
basal keratinocytes and dermal extracellular matrix; these antigens are BP180, a transmembrane
glycoprotein consisting of a globular cytoplasmic N-terminal domain, a short transmembrane
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stretch and a large extracellular C-terminal domain containing
15 collagenous repeats (4–7), and BP230, a protein of the
hemidesmosomal inner plaque with a central rod domain
flanked by globular end domains (4, 5). In addition
to IgG also IgE autoantibodies are involved in disease
pathogenesis and could be detected in the skin and/or
serum of BP patients by means of immunofluorescence
studies, immunoblot/immunoprecipitation and enzyme-linked
immunoassay (ELISA) analyses (8). Whilst the crucial role of
these autoantibodies in triggering the inflammatory cascade is
fully acknowledged (9), many ancillary mechanisms involved
in the complex etiology of BP need to be elucidated yet (10). In
this regard, the development of animal models, which include
the transfer of autoantibodies to experimental animals, the
adoptive transfer of autoantigen-specific B lymphocytes to
immunodeficient mice and immunization-induced models,
greatly contributed to dissect these pathogenic aspects (11). This
review provides a breakdown of the most recent studies on the
pathogenic mechanisms involved in BP.
ESTABLISHED STATUS OF KNOWLEDGE
ON BULLOUS PEMPHIGOID
PATHOGENESIS
It has been recognized that a combination of genetic predisposing
factors, such as class II HLA (e.g., HLA-DQβ1∗0301) (12),
and environmental influences, such as UV radiation, traumas,
and drugs, may contribute to the loss of immune tolerance
toward the above-mentioned antigens of the dermal-epidermal
junction (13). As shown in Figure 1, it has also been suggested
that the imbalance between autoreactive T helper (Th) and T
regulatory (Treg) cells (14, 15) as well as a T cell-independent
activation of toll-like receptor (TLR) system (16) may induce
B cell stimulation, with consequent BP autoantibody secretion.
In parallel, the Th17 pathway activation appeared to maintain
the inflammatory cascade started by humoral hyperactivation, by
triggering Th2 response, recruiting neutrophils and eosinophils
and stimulating the release of proinflammatory cytokines and
proteolytic enzymes (14, 17).
While the role of IgA or IgM is still elusive and their deposits
did not seem to affect the disease course (18), the role of IgE
is controversial. Some authors demonstrated that their deposits
along the basement membrane zone (BMZ) or their serum levels
correlated to specific BP clinical features, namely more infiltrated
lesions, such as urticarial plaques (18–20) or nodules (21),
while other ones observed no association between circulating
anti-BP180 IgE antibodies and a non-bullous urticaria-like
presentation (21, 22). Furthermore, serum anti-BP180 IgE levels
were shown to reflect disease activity throughout the course of
the disease (21, 22), even if it has been suggested that it might not
happen in the early phases of medication (23). However, on direct
immunofluorescence studies IgG are usually predominant. Mihai
et al. (24) showed that IgG1 and IgG4 were the most frequent IgG
subtypes found in BP along the dermal-epidermal junction. By
means of a cryosection assay, the same authors proved also that
IgG1 promoted blister formation through complement fixation,
whereas IgG4, which cannot fix the complement, activated
leucocytes and induced dermal-epidermal separation with a
lower pathogenic potential as compared to IgG1 (24).
BP180 is the main BP autoantigen and IgG and/or IgE
against this antigen may be detected in most patients (8).
The immunodominant non-collagenous region 16A (NC16A)
of the BP180 ectodomain is extensively accepted to be the
main target for BP autoantibodies. However, also domains of
BP180 outside of NC16A, such as the C-terminal domain of
BP180 and a 120-kDa fragment of BP180 known as LAD-1,
may be recognized (25–27). The IgG directed against BP180
domains other than NC16A seemed to be responsible of less
inflammatory manifestations (28) due to the fact that they
hardly induce any BP180 depletion respect to anti-BP180-NC16A
IgG in experimental studies (29). Moreover, IgG reactivity
with extracellular but not intracellular epitopes of BP180
paralleled the severity of the disease course (25) and higher
levels of anti-BP180 IgG were associated with increased 1-year
mortality (30). The pathogenic role of IgG anti-BP180 has been
validated by the following remarks: (i) the induction of BP-
like lesions in mice in which anti-BP180-NC16A antibodies
had been passively transferred (31); (ii) the onset of BP-like
bullae and a human disease phenotype in BP180-knockout
mice rescued by the human ortholog after being injected
with IgG from BP patients (32); (iii) the direct correlation of
anti-BP180-NC16A antibody titers to disease activity (33, 34).
Anti-BP180 IgE antibodies showed also pathogenic features;
indeed, the pathogenicity of anti-BP180 IgE antibodies has been
demonstrated via an IgE hybridoma to LABD97, a component
of the shed ectodomain of BP180, which was injected in
severe combined immunodeficiency (SCID) mice with engrafted
human skin, with consequent development in the skin grafts
of eosinophil infiltration and histological subepidermal blisters
resembling those of BP (35). Furthermore, the injection of
total IgE isolated from two BP patients sera into human skin
grafted onto athymic nude mice induced erythematous plaques
reminiscent of those clinically seen in BP (36). Antibodies of the
IgG class reacting against BP230, combined or not with anti-
BP180 antibodies, are usually found in a smaller proportion of
BP patients (37). Although the actual pathogenic role of anti-
BP230 autoantibodies has been initially debated (38, 39), it has
been more recently well-documented (40, 41) and IgG reactivity
with intracellular epitopes of BP230 has been shown to correlate
to BP severity (25).
The pathogenic mechanisms cooperating in the blister
formation secondary to BP autoantibody binding to their targets
are complex andmay be subdivided into complement-dependent
and complement-independent ones. Indeed, IgG1 have been
demonstrated to start the inflammatory complement cascade
leading to the recruitment of neutrophils and eosinophils in
BP, and, consequently, to release of proteolytic enzymes in
an experimental mouse model of BP (42). In addition to
complement-mediated mechanisms, more and more evidence
emerges that also complement-independent pathways play a
fundamental role in BP pathogenesis. It has been postulated that
there may be a direct influence of autoantibodies in adhesion
functions of autoantigens. Indeed, Iwata et al. (43) disclosed that
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FIGURE 1 | Representative figure of the main pathogenic pathways implied in blister formation in patients with bullous pemphigoid.
serum IgG from BP patients could deplete cultured keratinocytes
of BP180 and decrease cell adhesion to the bottom of the
culture plate, thus suggesting that hemidesmosomes had an
insufficient adhesive function due to a reduced hemidesmosomal
BP180 content. Furthermore, Ujiie et al. showed that passive
transfer of BP autoantibodies caused BP180 depletion in lesional
skin independently by complement deposition in neonatal C3-
deficient BP180-humanized mice (44). The role of IgG4 in
inducing the blister formation without complement cascade
intervention has been supported by Dainichi et al., who
reported two cases of IgG4-positive BP without complement
activation (45). Mast cells also have been proposed to contribute
to BP development and the presence of IgE autoantibodies
especially in patients with urticarial lesions provided indirect
support to the idea that IgE autoantibodies contribute to tissue
damage and to certain distinct clinical features, most likely
by triggering mast cell and basophil histamine release (19).
Moreover, anti-BP180 IgG (46) and IgE (47) autoantibodies have
been demonstrated to elicit the internalization of BP180 also
through pinocytic mechanisms.
BLISTER FORMATION MECHANISMS:
UPDATE AND NEW THEORIES
Complement Cascade
The role of classical and, to a lesser extent, alternative pathways
of the complement cascade in BP blister formation is fully
acknowledged (48). The strength of this assumption basedmainly
on in vitro and ex vivo experimental models has been recently
reinforced by an observational study on a large cohort of BP
patients (n = 301) showing complement deposits in 83.1% of
skin biopsies (49). These authors proved also that complement
deposition was related to clinical and serological disease activity.
Similarly, Chiorean et al. (50) strengthened the relevance of
complement activation in BP pathogenesis by substantiating that
complement activation by autoantibodies ex vivo as measured
by the complement-fixation assay in serum correlated to disease
activity. Furthermore, Kasprick et al. (51) recently assessed
the impact of a mouse monoclonal IgG2 antibody inhibiting
the activation of complement component 1s (C1s), a classic
complement pathway-specific serine protease, on the classic
complement pathway inhibition. Using cryosections of human
skin incubated with serum of BP patients and a complement
source leading to complement deposition along the BMZ of skin
section, the authors confirmed that this monoclonal antibody
was able to block the classic complement pathway activation
in this model, thus providing favorable data for further studies
on anti-complement monoclonal antibodies in BP patients. On
the other hand, complement-dependent mechanismsmay trigger
independent ones in the blister formation process. Indeed, in
a recent knock-out mice and pharmacological inhibition study
(52), the activated fifth component of complement (C5a) along
with its receptor 1 (C5aR1) appeared to be involved in the
early phase of the disease, while C5a receptor 2 (C5aR2) seemed
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to be protective. Thus, as soon as the inflammatory process
has completely developed, reactive oxygen species (ROS) and
proteases are released, particularly by neutrophils and mast cells,
regardless of complement involvement (45).
Pinocytosis
In accordance with the hypothesis that anti-BP180 IgG
may induce BP180 internalization from the keratinocyte cell
membrane through pinocytosis (44), Tie et al. (53) showed
that human keratinocytes incubated with BP IgG display
dysfunctional mitochondria, increased production of ROS,
and intercellular vesicle formation, leading eventually to
keratinocyte detachment.
Cytokine Profile
Unlike other skin inflammatory diseases, the key cytokines
orchestrating the inflammatory cell recruitment in BP lesional
skin have not yet been fully elucidated. However, a recent study
(17) highlighted the central role of interleukin (IL)-17A, showing
that mRNA levels of IL-17A were upregulated in perilesional skin
of BP patients. Moreover, using cryosection of normal human
skin and in mice, the same authors showed that inhibiting IL-17
with anti-IL-17 antibodies prevented BP180 IgG-induced blister
formation. In addition, in the antibody transfer mouse BPmodel,
IL-17A levels paralleled disease severity (17). Furthermore, the
contribute of TNF-related weak inducer of apoptosis (TWEAK),
a member of the TNF superfamily, and TWEAK/Fibroblast
growth factor-inducible 14 (Fn14) interaction in inducing blister
formation in BP has been investigated by Liu et al., who
showed that TWEAK serum levels correlated inversely to
BP180 expression and cellular adherence. Moreover, TWEAK
activation resulted to trigger inflammation via extracellular
signal–regulated kinases (ERK) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathways (54).
IgE, Eosinophils, and Mast Cells
Eosinophilic lesional infiltrates and peripheral eosinophilia are
well-known features of BP (55–57). High levels of cytotoxic
proteins stored in the secretory granules, such as eosinophil
cationic protein and major basic protein, as well as a Th2
milieu associated with augmented levels of IL-4, IL-5, and
IL-13, the main cytokines involved in eosinophil biology, are
usually seen both in lesional skin and serum of BP patients
(55, 58). In addition, eosinophils have been recognized also
as a major source of IL-31, a cytokine playing a significant
role in itch-related inflammation, in BP (59). The release of
matrix metalloproteinase-9 (MMP-9) and the production of ROS
have been found to be one of the main events depending on
eosinophil involvement (56, 60). In addition, eosinophils have
been hypothesized to have a strict relationship with anti-BP180
IgE autoantibodies, whose pathogenic role in BP has increasingly
recognized in recent years (61, 62). Lin et al. recently proved
that eosinophils are crucial for IgE-mediated blister formation,
showing that binding of anti-BP180-NC16A IgE to basal
keratinocytes induced eosinophil recruitment in a humanized
high-affinity IgE receptor (FcεRI) mouse model of BP (63).
Moreover, the interplay between FcεRI, that have been observed
to be highly expressed on eosinophils in BP patients (64), and
anti-BP180 IgE resulted essential in eosinophil degranulation
and consequent blister formation (63). Conceivably, FcεRI plays
a fundamental role also in activation of mast cell-induced
inflammation in BP lesional skin (65).
Coagulation Cascade
Eosinophils have also been demonstrated to be the main source
of tissue factor (TF), an initiator of blood coagulation, in
BP, representing an important link with the activation of the
coagulation cascade, an ancillary mechanism contributing to
blister formation. Moreover, plasma and blister fluid F1+2
prothrombin fragments (F1+2) and D-dimer levels paralleled
blood and tissue eosinophilia. In turn, TF fostered the early
trans-endothelial migration of eosinophils (66) and increased
skin expression of adhesins and matrix metalloproteinases (67).
Furthermore, blister fluid levels of eosinophilic cationic protein,
a protein released during degranulation of eosinophils, positively
correlated to both F1+2 and D-dimer levels (68). These findings,
in conjunction with the higher expression of TF in skin biopsies
of BP patients as compared to healthy controls (69, 70), outline
the role of coagulation cascade in BP pathogenesis.
Regulatory T- and B-Cell Dysfunction
The essential role of Treg cells in preventing the spontaneous
generation of BP autoantibodies has been recently demonstrated
by Muramatsu et al. in a Stat6 (signal transducer and
activator of transcription 6) gene knockout scurfy mouse
model (40). The same authors identified autoantibodies to
BP180 and BP230 in patients with immune dysregulation,
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
and underlined an association between anti-BP180 antibody
levels and an eczematous skin phenotype (40). Moreover, the
absence of Treg cells led to the appearance of histological
subepidermal blisters in scurfy mice, with the production of
pathogenic autoantibodies targeting BP230 (41). Consistent with
these findings, Bieber et al. (71) demonstrated in pemphigoid
mouse models that Treg impair the migratory capabilities of
myeloid cells by downregulating their expression of β2-integrin
rather than their release of ROS, thus alleviating the disease
severity. In addition to Treg, also B regulatory (Breg) cells
have been hypothesized to play a pathogenic role in BP. In
fact, Liu et al. (72) showed that Breg cells from BP patients
had a proinflammatory cytokine profile and were defective
in suppressing CD4+ T cell proliferation and anti-BP180
autoantibody production, suggesting that Bregs play a pro-
inflammatory role rather than a regulatory role in BP.
Neutrophils and Monocytes
In addition to the well-recognized role of lymphocytes and
eosinophils, it is clearly established that a cross-talk among other
immune cells, notably neutrophils and monocytes, contributes
in BP pathophysiology. The role of monocyte/neutrophil
interaction in blister formation has been recently investigated by
de Graauw et al. (73), who have highlighted in an ex vivo BP
model that monocytes enhance the capability of neutrophils to
release MMP-9, thus resulting in a more pronounced pathogenic
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potential and dermal-epidermal splitting. In a recent study, Fang
et al. (74) provided strong evidence that BP blister fluid-derived
exosomes, a subtype of extracellular vesicles involved in the
transmission of inflammation signaling, recruited neutrophils
through the upregulation of C-X-C Motif Chemokine Ligand
8 (CXCL8).
Proteolytic Enzymes
Among proteolytic enzymes implied in blister formation,
neutrophil elastase, and MMP-9 are the most studied. However,
the role of other proteases, such as granzyme B is lately emerging.
Although its pro-apoptotic functions in cytotoxic T lymphocyte-
mediated are more well-known, Russo et al. have recently
displayed that granzyme B is elevated in the context of dermal-
epidermal junction of lesional BP skin and contribute to its
disruption by cleaving BP180 (75).





Several epidemiological studies have confirmed that patients
affected by neurologic and neurodegenerative diseases, such as
multiple sclerosis and Alzheimer’s disease, have an increased
risk of developing BP (76). Since BP180 has been described
to be expressed at low levels in neuronal tissue (77), it has
been argued that neurodegeneration or neuroinflammation may
lead to loss of self-tolerance toward BP180 and consequent
BP development. Although a certain degree of cross-reactivity
between BP180 and/or BP230 brain and skin isoforms exist
(78), a recent study (79) evidenced that in Alzheimer’s disease
and multiple sclerosis patients the autoantibodies against BP180
targeted epitopes different than those targeted in patients with BP
and did not bind natively folded BP180, thus suggesting their low
potential to induce BP. Future studies could investigate the role
of epitope spreading phenomenon in the induction of BP (80).
Vitamin D Deficiency
A higher prevalence of vitamin D deficiency and lower
25-hydroxyvitamin D levels were found in BP patients as
compared to controls by our group (81). An extended study
additionally showed that 25-hydroxyvitamin D levels inversely
correlated to disease severity (82). Indeed, vitamin D has
been shown to have an immune regulatory function and
hypovitaminosis D has been correlated to an increased risk
of developing autoimmune disorders (83). Moreover, vitamin
D3 has been revealed to elicit down-regulation of the BP230
gene through post-transcriptional mechanisms independently by
active protein synthesis (84), while non-toxic doses of calcitriol,
the hormonally active vitamin D metabolite, reduced the release
of the proinflammatory cytokines IL-6 and IL-8 induced by
purified human BP IgG from HaCaT cells (85). A similarly
beneficial effect of calcitriol has been recently reported also in
mice with experimental EBA (86).
Thrombosis
The risk of thrombosis and/or thromboembolism is augmented
in BP patients (87), as witnessed by a recent multicenter
cohort study showing that BP patients have a 4-fold increased
risk of developing venous thromboembolism compared to the
general population (88). Indeed, several studies revealed that
the inflammatory response in patients with BP activated the
coagulation cascade, which paralleled disease activity (66, 70,
89, 90). In particular, D-dimer and F1+2, two coagulation
activation markers, have been observed to be increased in blister
fluid, lesional skin and plasma (90), with F1+2 correlating to
the anti-BP180 levels (89). Moreover, during remission phases,
blood concentration of coagulation activation markers reverted
to normal (70). Therefore, extrinsic blood coagulation pathway
activation may be regarded as a contributory mechanism leading
to local inflammation and blister formation in BP (79, 80, 82).
Fibrinolysis resulted also inhibited in BP, chiefly due to increased
plasminogen activator inhibitor type 1 (PAI-1) activity and
plasma levels (91). Interestingly, the recent observation that
serum levels of soluble P-selectin, a marker of platelet activation,
were significantly higher in BP patients than controls led to
hypothesize a role of platelets in disease pathogenesis (92).
CONCLUSION
As highlighted in this review, the pathogenesis of BP is complex,
and evidence is growing that new ancillary pathomechanisms
flanking the traditional ones—e.g., IgG1-mediated complement
activation—may play a role in the events leading to subepithelial
blister formation.
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